Sanofi (ENXTPA:SAN) experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the ...

Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head, Immunology and Oncology Development, Sanofi said, “Until now, treating bullous pemphigoid was very challenging for elderly patients struggling ...

Investing.com -- Sanofi (EPA: SASY) (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) Pharmaceuticals received Food and Drug Administration approval for their anti-inflammatory drug Dupixent to treat a rare ...

Investing.com -- Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) Pharmaceuticals received Food and Drug Administration approval for their anti-inflammatory drug Dupixent to treat a rare skin disease ...

18.3% of patients on Dupixent achieved sustained remission vs. 6.1% on placebo at 36 weeks. Median corticosteroid use was 2.8g with Dupixent vs. 4.1g with placebo in BP patients. Get ahead of Wall ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Investing.com -- Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) Pharmaceuticals received Food and Drug Administration approval for their anti-inflammatory drug Dupixent to treat a rare skin ...

The two organisations signed a memorandum of understanding to this effect at the BIO International Convention 2025, in Boston, USA, recently. Dr Noura Khamis Al Ghaithi, Under-Secretary of the ...

Credit: Department of Health Abu Dhabi. The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local ...